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“Scientific work must not be considered from the point of view of the direct 
usefulness of it. It must be done for itself, for the beauty of science” 
Marie Curie (1867-1934) 
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Resumo 
O design e síntese de sistemas eficazes de libertação de fármacos (SLD) é extremamente 
importante para a área da engenharia de tecidos e medicina regenerativa (TERM). Estruturas 
optimizadas com uma distribuição e uma cinética de liberação bem definidas são pré-requisitos 
para uma aplicação clínica segura e eficaz, evitando efeitos colaterais indesejáveis e toxicidade. 
Visando o desenvolvimento de SLD de aplicação minimamente invasiva, aliada a uma libertação 
sustentada, prolongada e localizada de sinais bioquímicos relevantes para a regeneração do 
tecido, foi desenvolvido neste trabalho um SLD injetável bifásico, o qual resulta da combinação de 
micropartículas (MPs) de poli(hidroxibutirato-co-hidroxivalerato) (PHBV) (MPs) com um hidrogel de 
goma gelana (GG). 
A primeira etapa do trabalho apresentado nesta dissertação consistiu na produção de MPs de 
PHBV, com incorporação de moléculas modelo de proteínas e glucocorticóides. Para este efeito, 
foram incorporadas dentro de MPs de PHBV Albumina de Soro Bovino (BSA) e Dexametasona 
(Dex) usando um método de dupla emulsão A/O/A com evaporação do solvente, após algumas 
modificações. Visando o controlo adequado do perfil de liberação de moléculas bioactivas, como 
fase orgânica foram usadas diferentes proporções de clorofórmio e etanol. Algumas características 
do sistema de MPs foram afectadas pela modificação do método, nomeadamente o tamanho das 
partículas, bem como a topografia da superfície das mesmas. A influência da presença de etanol 
na fase orgânica também foi avaliada em termos de eficácia de incorporação das moléculas 
bioactivas, sendo que a sua presença conduziu a uma maior eficácia na incorporação de Dex, 
enquanto a incorporação de BSA não foi afectada. Por sua vez, os estudos de libertação in vitro 
revelaram que MPs produzidas na ausência de etanol na fase orgânica apresentam um perfil de 
libertação mais sustentado quando comparado com as MPs produzidas na presença de etanol. 
Estes resultados eram esperados uma vez que a adição de etanol à fase orgânica induziu a 
formação de poros maiores na superfície e no núcleo das MPs, proporcionando deste modo a 
penetração de água, e consequentemente a libertação mais rápida das moléculas bioactivas. 
Após a obtenção das MPs de PHBV com incorporação de moléculas de interesse para a área de 
TERM, o objectivo foi definir um sistema que actuaria como um sistema de transporte das MPs, 
contribuindo para aumentar o tempo de residência das MPs no local de injecção. Para este efeito, 
as diferentes MPs de PHBV foram incorporados nos hidrogéis injectáveis de GG, amplamente 
estudado no nosso grupo de investigação para diferentes aplicações de engenharia de tecidos. As 
MPs de PHBV incorporadas no hidrogel apresentam-se uniformemente distribuídos na matriz, 
demonstrando, também, uma forte integração com o polímero do hidrogel. Como esperado, a 
incorporação das MPs nos hidrogéis de GG influenciou fortemente o perfil de libertação, obtendo-
se sistemas de libertação de ordem zero. Embora as propriedades do hidrogel possam ser 
modificadas de um modo controlado, com o objectivo de ajustar o perfil de libertação de acordo 
com requisitos específicos dos tecidos e da patologia/lesão, o sistema proposto pode, certamente, 
ser explorado como uma SLD de longo prazo. 
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Neste sentido, um SLD bifásico, que permite a libertação de sinais bioquímicos com diferentes 
características físico-químicas, bem como a sua libertação localizada, foi desenvolvido com 
sucesso e constitui uma ferramenta versátil de modulação de microambientes celulares instrutivos 
para aplicações em TERM. 
A dissertação foi estruturada em diferentes capítulos: I) uma introdução que fornece uma visão 
geral dos conceitos básicos de sistemas de MPs, MPs poliméricas com base na sua formulação, 
mecanismos de entrega de moléculas bioactivas, e aplicações em TERM; II) a secção de Materiais 
e Métodos que descreve detalhadamente os materiais utilizados para o desenvolvimento das MPs 
e dos hidrogéis, bem como as respectivas metodologias de processamento e caracterização, III) o 
manuscrito completo que resultou do trabalho realizado, o qual se encontra estruturado num breve 
resumo, uma introdução mais concisa, o resumo dos materiais utilizados e das metodologias 
seguidas ao longo do trabalho, descrição dos resultados e subsequente discussão e uma breve 
conclusão; IV) as conclusões finais do trabalho e perspectivas futuras do sistema desenvolvido na 
área de TERM. 
 
Palavras-chave: Sistemas de libertação de fármacos, Engenharia de Tecidos, poli(hidroxibutirato-
co-hidroxivalerato), micropartículas, hidrogel injectável 
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Abstract 
Design and synthesis of efficient drug delivery systems (DDS) are of vital importance for tissue 
engineering and regenerative medicine (TERM). Optimized delivery structures and well-defined 
release kinetics appear to be logical prerequisites for safe and efficacious clinical application 
avoiding undesired side effects and toxicity. With a view toward developing DDS to be applied 
using minimally-invasive approaches, and that would provide sustained, prolonged and localized 
release of biochemical cues relevant for tissue regeneration, we designed a biphasic injectable 
DDS combining polyhydroxybutyrate-co-hydroxyvalerate (PHBV) microparticles (MPs) within a 
gellan gum (GG) hydrogel. 
The production of PHBV MPs incorporating proteins and glucocorticoids model molecules was the 
first step of the work presented in this dissertation. For this purpose, Bovine Serum Albumin (BSA) 
and Dexamethasone (Dex) were incorporated inside PHBV MPs by using a double emulsification-
solvent evaporation method with modifications. Aiming at tailoring the bioactive molecules release 
profile, different proportions of chloroform and ethanol, as organic phase, were proposed. This 
modification revealed to affect some features of the microparticulate system, namely particle size 
and surface topography. The influence of the presence of ethanol in the organic phase was also 
evaluated in terms of bioactive molecules incorporation efficiency. The presence of ethanol led to 
higher efficiency of Dex entrapment inside the MPs, while the BSA incorporation was not affected. 
In his turn, the in vitro release studies revealed that MPs produced in the absence of ethanol in the 
organic phase presented a more sustained profile when compared to the MPs produced in the 
presence of ethanol. This finding was expected since the addition of ethanol to the organic phase 
induced the formation of larger pores on the surface and in the core of the MPs thus facilitating 
water penetration, and consequently faster release of the bioactive molecule. 
After obtaining the PHBV MPs loaded with the molecules of interest, the objective was to define a 
system that would act as carrier of the MPs and would enhance MPs residence time upon injection. 
For this purpose, the different PHBV MPs were embedded within injectable GG hydrogels, 
extensively studied in our Research Group as cell carriers for different tissue engineering 
applications. A uniform distribution of PHBV MPs across the GG matrix with a strong integration of 
the MPs with the polymer of the hydrogel was attained. As expected, the incorporation of the MPs 
into the GG hydrogels strongly influenced the profile, from one to nearly zero-order and the amount 
of released Dex and BSA. Although the properties of the hydrogel are prone to further improvement 
in order to tune the release profile according to tissue and pathology/injury specific requirements, 
the proposed system can certainly be explored as a long-term DDS.  
In this sense, a biphasic DDS, which allows the release of biochemical cues with different 
physicochemical features, as well as its localized deliver, was successfully developed and 
represents a versatile tool to prepare instructive cell microenvironments for TERM. 
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The dissertation was structured in different chapters: I) a General Introduction that provides an 
overview of the basics of microparticulate systems, polymeric microparticles based on their 
formulation, their mechanisms of drug delivery, and their applications in the TERM; II) a Materials 
and Methods section that describes with some detail the materials used to produce the MPs and 
the hydrogels as well as the respective processing and characterization methodologies; III) the 
complete manuscript that resulted from the work developed in which is provided a short abstract, a 
more concise introduction of the work, a resume of the materials used and methodologies followed 
along the work, the description of the results and subsequent discussion; IV) the final conclusions 
of the work and future perspectives for the area.  
 
Keywords: Drug Delivery System, Tissue Engineering, polyhydroxybutyrate-co-hydroxyvalerate, 
microparticles, injectable hydrogel 
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I. General Introduction 
1. Drug Delivery Systems  
Drug Delivery is a field of vital importance for medicine and healthcare (Zhang, 2013). 
This field of pharmaceutical technology represents one of the most rapidly advancing 
areas of science in which chemists and chemical engineers are contributing to human 
health care (Jain, 2008). 
Therapeutic efficacy and safety of drugs, administered by conventional methods, can be 
improved by more precise spatial and temporal placement within the organism, thereby 
reducing both the size and number of doses by using a controlled drug delivery system 
(DDS) (Bassyouni, 2013). Indeed, the DDS plays a vital role in controlling the 
pharmacological effect of the drug as it can influence its pharmacokinetic profile, release 
rate, the site and duration of its action and subsequently the side-effect profile (Perrie, 
2010).  
Controlled DDS improves bioavailability by preventing premature degradation and by 
enhancing uptake, maintains drug concentration within the therapeutic window by 
controlling the drug release rate, and reduces side effects by targeting diseased site and 
specific cells (Zhang, 2013). The release of the bioactive molecule is extended along with 
the time which is highly beneficial for molecules that are rapidly metabolized and 
eliminated from the body after administration (Jain, 2008). With this kind of release 
systems, the rate of drug release matches the rate of drug clearance and, therefore, the 
drug concentration is within the therapeutic window for the vast majority of the 24 hours 
period.  
Tissue engineering (TE) was defined by Langer and Vacanti in 1993 as “an 
interdisciplinary field of research that applies the principles of engineering and life 
sciences towards the development of biological substitutes that restore, maintain, or 
improve tissue function”. In this research domain, the general strategy consists in 
developing biodegradable/biocompatible scaffold materials that play an important role as 
artificial extracellular matrix (ECM) in which cells are seeded/cultured, under pre-
determined conditions, with defined biochemical and mechanical cues (Hutmacher, 2000). 
Nevertheless, they are often unable to create the exact/correct microenvironment during 
the engineered tissue development to promote the accurate in vitro tissue development. 
The emerging and promising next generation of engineered tissues is relying on 
producing scaffolds with functional cues (Malafaya, 2007) aiming at driving host healing 
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response at the site of injury. In order to produce biofunctional engineered tissues, 
researchers have been combining scaffolds with cells from assorted sources and/or 
growth factors (GFs) to stimulate cell migration, differentiation and tissue remodelling 
(Xiao, 2003; Kanczler, 2008; Anderson, 2009; Chen, 2010). With an improved 
understanding of the critical pathways involved in the development of integrated tissues, 
the role of GFs in tissue regeneration, and the expansion of their availability through 
recombinant technologies, the delivery of GFs by DDS is an increasingly important 
strategy to repair or regenerate damaged/diseased tissue and is a leading component of 
tissue engineering approaches. 
In the context of tissue engineering, an ideal DDS must have several general 
requirements, including being a biodegradable carrier material, possess high loading 
efficiency, a controlled release profile, the ability to target or be retained at the desired site 
of action, and ideally a certain degree of versatility that for example allows several 
bioactive molecules to be sequentially released in a manner that mimics the temporal 
profile of the healing process in vivo (Vasita, 2006; Chen, 2009a; Balasubramanian, 2010). 
Simultaneously, several factors, such as the properties of the drug/bioactive molecule, 
route of administration, nature of delivery vehicle, mechanism of drug release, ability of 
targeting, and biocompatibility must be taken in consideration (Figure 1) (Chiellini, 2008).  
 
 
Figure 1 – Requisites regarding the design of a new drug delivery system (adapted from Chiellini, 
2008). 
Drug Properties 
Route of 
Administration 
Biocompatibility 
Ability of 
Targeting 
Mechanism of 
Drug Release 
Delivery System 
Properties 
Controlled 
Drug 
Delivery 
Systems 
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The use of molecular or macromolecular entities and derived superstructures concerning 
the delivery of drugs has a long history. Antibodies, for instance, were suggested early in 
the last century as a mean to direct anticancer drugs to tumour cells in the body 
expressing the corresponding antigen (Ritz, 1982). Their use as monoclonal molecules is 
now in the vanguard of targeted therapy. Following advances in the discovery of cell 
receptors, receptor-binding macromolecules were added to the armamentarium of DDS 
for the targeting of drugs. In parallel, since the early 1970s, liposomes are at the forefront 
of drug and vaccine design owing to their well-documented abilities to act as delivery 
vehicles (Gregoriadis, 1993; Henriksen-Lacey, 2011). These superstructures, formed 
spontaneously from amphipathic lipid molecules, together with a diverse collection of 
other promising superstructures derived from a huge variety of natural and synthetic 
monomeric or polymeric units, have evolved to sophisticated versions of DDS. The 
incorporation onto their surface of macromolecules that contribute to optimal 
pharmacokinetics of actives and their delivery to where they are needed has been 
successively proposed (Vemuri, 1995; Fahy, 2009).  
Recently, the advances in the peptide, proteins and drug designs and the emergence of 
gene therapy have been intensifying the need for the development of new controlled 
release strategies (Jain, 2008). Their clinical success is considered to be dependent on 
the controlled release devices design, which must ensure that the drug release will 
perfectly reach the targeted cells at a specific time. A number of DDS are currently under 
investigation to circumvent the limitations commonly found in conventional dosage forms 
and to improve the potential of the respective drugs. These DDS have been envisioned as 
liposomes (Drulis-Kawa, 2010; Monteiro, 2013), micelles (Wilson, 2013; Xu, 2013), 
polymeric micro and nanoparticles (Joshi, 2013; Liang, 2013; Kozielski, 2013; Wang, 
2013), cyclodextrins (Chen, 2011; Dhule, 2012), among others (Oliveira, 2011a). 
 
2. Microparticles as Drug Delivery Systems 
There are various approaches to deliver a therapeutic substance to the target site in a 
sustained controlled release fashion. Of the different forms reported, microparticles 
attained much importance due to a tendency to accumulate in inflamed areas of the body 
(Puddu, 2010). The terminology used to describe microparticulate formulations can 
sometimes be inconsistent and confusing to readers unfamiliar with the field. Basically, 
the term “microparticle” refers to a particle with a diameter of 1-1000 μm, irrespective of 
the precise internal or external structure (Arshady, 1988; Freiberg, 2004). However, this 
criterion is very ubiquitous, and some researchers have been considering that, in terms of 
4 
 
diameter, microparticles cover a range between 0.1 and 2 μm (Shet, 2008; Puddu, 2010; 
Siljander, 2011, Press, 2012). Within the broad category of microparticles, microspheres 
specifically refers to core-shell microparticles, whilst the subcategory of microcapsules 
applies to microparticles which have a core surrounded by a material, distinctly different 
from that of the core, which can be solid, liquid, or even gas (Chemtob, 1986; Brazel, 
2000; Berkland, 2004). 
A number of different polymers, both synthetic and natural, have been exploited for the 
fabrication of biodegradable microparticles (Oliveira, 2011b). Synthetic polymers have the 
advantage of sustaining the release of the encapsulated therapeutic agent over a period 
of days to several weeks. In opposition, natural polymers have a relatively short duration 
of drug release and are in general limited by the use of organic solvents and relatively 
harsher processing conditions (Panyam, 2003).  
The most frequently used polymers for this purpose include poly(lactic acid) (PLA), 
poly(glycolic acid) (PGA), their copolymers poly(lactic-co-glycolic) acid (PLGA), poly-ε-
caprolactone, polyethylene, polymethyl methacrylate, oligo(poly(ethylene glycol) fumarate) 
(OPF), microparticulate systems; natural polymers such as poly(hydroxybutyrate) (PHB), 
its copolymers poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV), alginate or gelatin 
(Vasita, 2006; Balasubramanian, 2010). In addition, inorganic materials such as low and 
high temperature calcium orthophosphates (including calcium phosphate cements and 
sintered ceramics), calcium sulphate cements and Bioglass have also been used as GF 
carriers (Chen, 2009b). 
 
2.1. Microparticulate Systems in Tissue Engineering 
Controlled release has many direct applications to TE. For example, local delivery of GFs 
can be accomplished by encapsulating the agent within a biocompatible polymer matrix or 
microparticle. The controlled-release polymer system is then implanted at the desired 
tissue site, where it releases the soluble factor directly into the interstitial space of the 
tissue (Saltzman, 2002). 
GFs can be incorporated into the scaffolds by two approaches. The first approach 
involves adding a lyophilized factor like vascular endothelial growth factor (VEGF) to the 
polymeric microparticles prior to processing the polymer into a porous scaffold, which 
results in the factor being largely associated with the surface of the polymer. In this 
method, VEGF is subjected to rapid release (e.g., days to weeks in duration). The second 
approach involves pre-incorporation of a GF in microspheres. Therefore, fabricating 
scaffolds from these particles results in a more even distribution of factors throughout the 
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polymer, with release kinetics controlled by degradation rate of the polymer used to 
construct microparticles. The two approaches may be combined by mixing particulate 
polymers containing the first factor with microspheres containing a pre-encapsulated 
second factor to deliver two GFs with different release rates. The particulate and 
microparticles are then fused to form a homogeneous combined scaffold with an open-
pore structure (Richardson, 2001). 
 
2.1.1. Microparticulate Drug Delivery Systems  
Therapeutic induction of tissue repair or function restoration in tissue engineering and 
regenerative medicine requires recapitulation of the spatial and temporal 
microenvironments presented by natural ECM, in many cases by providing exogenous 
instructive bioactive signals (Biondi, 2008). The identification and production of 
recombinant morphogens and GFs that play key roles in tissue regeneration have 
generated much enthusiasm. Pivotal among these signals are GFs, a group of proteins 
capable of acting on cell-surface receptors and directing cellular activities involved in 
wound healing, such as bone morphogenetic proteins (BMPs, particularly BMP-2, -4 and -
7), VEGF, epidermal growth factor, and fibroblast growth factor, which provide vital 
stimulation of cell recruitment, proliferation, morphogenesis, and differentiation (Tabata, 
2000; Chen, 2010).  
To be effective as a therapeutic agent, a GF has to reach the site of injury without 
degradation, and then, it has to remain in the target location sufficiently long to exert its 
action(s) (Chen, 2009b). GFs that are provided exogenously in solution into the site to be 
regenerated are generally not effective because GFs tend to diffuse away from injury sites 
and to be enzymatically digested or deactivated (Chen, 2009b; Chen, 2010). Interestingly, 
clinical trials of DDS that have shown benefit all contain a common denominator, the 
presence of a material carrier, strongly suggesting that spatiotemporal control over the 
location and bioactivity of factors after introduction into the body might be achieved by the 
use of those carriers (Lee, 2011). 
In the search for vehicles that delivery without being damaged, microparticulate systems 
made of biodegradable polymers as reveal significant advantages when incorporating 
GFs. These systems have the potential to provide sustained release kinetics in remote 
parts of the body after implantation (Chen, 2010). The release profile of a GF can be 
altered either by tailoring the properties of the polymer or polymeric composition or even 
by adjusting the physical and chemical properties of the microparticles such as surface 
porosity, particle size, and its degradation rate (Chen, 2007; Chen, 2009b). Moreover, the 
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drug loading capacity of particulate systems can be greatly improved if a capsule is 
formed or if the core of each microsphere is designed to have an interconnected pore 
structure. Microparticles are not internalized by the cells and are retained in the tissue, 
providing prolonged bioactive substance release. Additionally, it is not easy for 
microparticles to diffuse out of the target tissue to other sites to cause deleterious side-
effects in other tissues because of their size. Thus, they provide good control over the 
release rate and dose of GFs in a local microenvironment, yielding desirable 
concentrations over a period of days or months (Varde, 2004; Anitua, 2008; Mundargi, 
2008). 
Microparticles carrying GFs, small molecules, among others have been prepared by 
various techniques and their role has been investigated both in in vitro and in vivo. PLGA - 
based microcapsules containing GFs have been prepared by a double emulsion–solvent 
evaporation technique (Wenk, 2009). In 2008, Rocha and co-workers showed that the 
sustained delivery of VEGF encapsulated in PLGA microspheres interferes with wound 
healing cascade events and its release upregulates angiogenesis (Rocha, 2008). The 
degree of encapsulation and mechanism of growth factor entrapment are dependent on 
hydrophobic–hydrophobic or hydrophilic–hydrophilic interactions among the molecules 
and polymers. Blending of materials allow more complex structures and patterns of factor 
entrapment (Lee, 2011). In 2009, Zhu and collaborators have proposed a blend of PLGA 
and PHBV microparticles prepared by an emulsion technique to release of hepatocyte 
growth factor (Zhu, 2009). The final microparticulate structure showed a core-shell 
structure, where PHBV molecules, which are more hydrophobic and less degradable, 
were distributed within the shell. This prevents the loss of GFs during processing, 
resulting in a better encapsulation material than microspheres of PLGA- or PHBV-alone 
(Zhu, 2009). Recent studies with calcium phosphate cement /gelatin composite and 
diopside (CaMgSi2O6) ceramic microspheres showed that ceramic microparticle systems 
can be successfully used as injectable, biodegradable and osteoinductive delivery 
vehicles (Leeuwenburgh, 2010). Kirby and co-workers also demonstrated that 
PLGA/PLGA-PEG-PLGA microparticles entrapping and releasing BMP-2 in a sustained 
manner promote the differentiation of MC3T3-E1 cells to a greater extent than osteogenic 
supplements (Kirby, 2011).  
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2.1.2. Microparticulate Drug Delivery Systems as part of Tissue Engineering 
Scaffolds 
When microparticles are injected in target tissues, they are continuously exposed to 
external mechanical deformation, leading to the uncontrollable displacements of particles 
(Fitzgerald, 1987; Griffith, 2000; Chan, 2005). This displacement greatly affects the 
concentration of bioactive macromolecules in target tissues, resulting in limited tissue 
regeneration (Lemperle, 2004). Moreover, when in free movement the particulate system 
can be expelled even before release of the therapeutic agent. Furthermore, these 
approaches for therapeutic tissue regeneration usually involve one-time delivery of single 
biochemical cues. Therefore, extensive efforts are being made to tackle these limitations 
while harnessing the advantages of particulate systems, including their minimally invasive 
delivery and controlled drug release.  
The development of sophisticated drug delivery systems with multiple functionalities is 
one of the challenges of TE. Extraordinary progress has been made in the last years 
regarding the design of scaffolds with suitable multiscale hierarchical structure and toward 
the design of delivery systems able to release active molecules following a hypothetically 
complex delivery pattern (Biondi, 2008). 
Current TE strategies are focusing on the development of porous scaffolds specifically 
designed to mimick tissues ECM at morphological but most importantly at biochemical 
level by incorporating bioactive components, selected to promote full regeneration 
(Guldberg, 2009). In this sense, the concept of particulate systems further associated with 
3D scaffolds (Chen, 2007; Chung, 2007; Fei, 2008) serves two functions, as a scaffolding 
structure for cell attachment and tissue ingrowth, as well as a delivery platform for multiple 
bioactive molecules release. A variety of systems have been designed with this purpose. 
Chen and co-workers proposed a dual release system of BMP-2 and Insulin-like Growth 
Factor-1 (IGF-1) from gelatin microparticles embedded in a glycidyl methacrylated dextran 
hydrogel for periodontal TE purposes (Chen, 2009b). In this study, it was shown that the 
system allowed the release of both proteins in a sustained and independent fashion, 
which facilitated cell attachment, proliferation and osteoblastic differentiation of 
periodontal ligament fibroblasts in a synergistic manner. The effect of simultaneous, 
controlled release of VEGF and monocyte chemotactic protein-1 from dual particulate 
systems as a strategy for therapeutic vascularization was proposed by Jay (2010) and 
collaborators. Alginate microparticles loaded with both VEGF and MCP-1 with distinct 
release kinetics were integrated into a collagen/fibronectin gel used as endothelial cells 
(EC) carrier. The combined delivery of VEGF and MCP-1 increased functional vessel 
formation from transplanted EC and also led to a higher number of smooth muscle cell-
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invested vessels than did EC therapy alone. Despite the well-known role of MCP-1 in 
inflammation, these beneficial effects were accomplished without a long-term increase in 
monocyte/macrophage recruitment or a shift to a pro-inflammatory (M1) macrophage 
phenotype. More recently, stem cells encapsulated in OPF hydrogels combined with 
transform growth factor (TGF)-β3 and/or IGF-1-loaded gelatin MPs were proposed for 
osteochondral tissue regeneration by Kim et al. (2013). In this study, a bilayered OPF 
hydrogel that intended to mimic the distinctive hierarchical structure of native 
osteochondral tissue was used to assess the effect of TGF-β3 with varied release kinetics 
on osteochondral tissue regeneration in a rabbit full-thickness osteochondral defect 
model. The in vivo study revealed that after 12 weeks post-implantation IGF-1 delivery 
alone contributed to enhanced cartilage repair in comparison to the dual GFs delivery. 
Additionally, no significant effects of the TGF-β3 release kinetics were observed on 
osteochondral tissue repair. The results suggested that the dual delivery of TGF-β3 and 
IGF-1 may not synergistically enhance the quality of engineered tissue, revealing that 
combined and complex approaches do not necessarily confer improved healing over the 
single delivery of GFs, and that most likely the approach to follow is highly dependent on 
the TE application. Thus, although current evidences suggest that well-chosen GFs 
cocktails can represent an advantage when associated in simultaneous delivery systems, 
uncertainties whether reciprocal or cooperative interactions exist as fare to be clear. 
 
2.1.3. Microparticulate Drug Delivery Systems as Tissue Engineering Scaffolds 
The use of microparticles as scaffolds is a relatively poorly explored TE approaches that 
has many advantages, mainly due to its versatility (Borden, 2002; Lu, 2003; Zhang, 2003; 
Ungaro, 2006). In fact, microspheres can be easily modified in a controlled manner (Hong, 
2005) to introduce various ECM proteins aiming to tailor the cell-material interaction 
promoting cell adhesion. Simultaneously, GFs as well as other bioactive molecules can be 
easily incorporated and then further released in a controlled manner from the 
microspheres that acted as scaffolding structures themselves, thus regulating cell 
behavior (Tabata, 1999; Perets, 2003; Chen, 2003). The so-called microparticles 
aggregation method consists in their aggregation, by physical or chemical means, forming 
those 3D structures (Maquet, 1997) that can provide support for cell adhesion and also 
act as carriers of bioactive molecules (Gomes, 2005). For microsphere-based scaffolds, 
microsphere size is one of the major determinants of polymer degradation rate, governing 
the release kinetics of loaded molecules and providing the control over pore sizes and 
macro-porosity (Singh, 2008). 
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A different approach was developed by Nof and co-workers (Nof, 2002) which produced 
PLGA microspheres by double emulsification process incorporating a DNA plasmid and 
further designed using a gas foaming technique to create the 3D porous structures of 
different shapes. The obtained scaffolds exhibited a sustained plasmid release for at least 
21 days with minimal burst effect during the initial phase, which differed from the first 24 
hours release profile from individual microparticles. In a study by Malafaya et al., a novel 
approach was used envisioning osteochondral regeneration by effective differentiation of 
adipose tissue-derived mesenchymal stem cells in osteogenic and chondrogenic media. 
In this study, scaffolds were obtained by the agglomeration of chitosan microparticles 
using a heat-induced process. Osteochondral bilayered scaffolds were also developed 
consisting of a hydroxyapatite part and another made up of chitosan, linked by chemical 
crosslinking process, leading to an integrative bone and cartilage interface (Malafaya, 
2005). 
 
3. Final Remarks and Future Trends 
Successful repair and regeneration strategies will require quantitative insight of tissue 
microenvironment and can be engineered via designing biomaterials, which provide 
quantitative adhesion, growth, or migration signals to direct cellular differentiation 
pathways. The use of microparticles in the health sciences has been adapted to TE 
strategies in several approaches. Advances in bioactive materials as well as DDS allow 
not only controlled release, but also protection of bioactive molecules from degradation. 
The combination of microparticles with TE scaffolds allow the control over local 
concentrations needed and/or local concentration gradients needed for successful tissue 
regeneration. Moreover these systems can be processed into a scaffold constituting a 
versatile platform for cell adhesion and bioactive molecules release.  
From an upstream perspective, an effort is being made to develop scalable differentiation 
technologies and to study morphogen gradients in pluripotent stem cell differentiation by 
using localized delivery of GFs within multicellular aggregates from microparticle delivery 
vehicles. For this purpose, some advances are being made and researchers have 
reported gelatin-based microparticles to deliver GFs to specific areas of embryoid bodies 
as aggregates of differentiating stem cells. Although huge developments have being 
made, these release technologies in TE&RM is not yet delivering significant progress in 
terms of clinical outcomes and commercialization, this fascinating field of research is 
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bound to dramatically change clinical practice and the therapeutic choices made by 
clinicians, resulting in significant therapeutic commercial devices and in vitro models. 
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II. Materials and Methods 
1. Poly (hydroxybutyrate-co-hydroxyvalerate) Properties 
Polyhydroxyalkanoates (PHAs) are produced by a wide variety of microorganisms as an 
internal carbon and energy storage, as part of their survival mechanism (Doi, 2002; Jung, 
2005). Poly (hydroxybutyrate-co-hydroxyvalerate) (PHBV) is a member of PHAs, which 
together with is homopolymer poly(hydroxybutyrate) (PHB) are the most widely used in 
Tissue Engineering and Drug Delivery Systems. In terms of physicochemical features, 
PHBV is thermoplastic optically active polyester which is insoluble in water and exhibit a 
high degree of polymerization (Scandola, 1997; Kang, 2001). These polymers also 
present some interesting characteristics, namely antioxidant (i.e. inhibits the oxidation of 
other molecules) and piezoelectric properties, i.e. the capacity of a material to suffer 
electric polarization due to mechanical stress (Chen, 2000). PHB and PHBV, which are 
members of PHAs family, degrade into d-3-hydroxybutyrate acid, which is a normal 
constituent of human blood, which may justify their low toxicity (Tokiwa, 2004; Choi, 2005; 
Cheng, 2006). PHB is very crystalline and brittle, whereas the copolymers of PHB with 
hydroxyvaleric acid (PHBV) are less crystalline (Srithep, 2013), more flexible, and more 
processable (Barham, 1984; Yu, 2006).  
 
2. Gellan Gum Properties 
Gellan gum (GG) is one of the widely used fermentation materials, which offers a solution 
to many problems encountered in gelling agents, which is resistant to heat and acid 
(Prajapati, 2013). GG is an extracellular microbial anionic heteropolysaccharide consisting 
of glucose–glucuronic acid–glucose–rhamnose as a repeating unit and that forms a gel in 
the presence of metallic ions (Kang, 1982; Jansson, 1983). It is commercially available in 
two forms, acetylated and deacetylated both forming thermo-reversible gels with different 
mechanical properties in the presence of metallic ions and upon temperature decrease. 
The key advantages of GG are its high gelling efficiency and its ability to produce a wide 
spectrum of mechanical properties (Sworn, 2009). GG also requires concentrations two to 
three times less than those of gelatin and agar to achieve the similar levels of mechanical 
strengths (Morris, 2012). Moreover, GG based hydrogels have been shown to efficiently 
sustain the deliver and growth of human cells for different tissue engineering applications 
(Silva-Correia, 2012). 
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3. Preparation of Poly (hydroxybutyrate-co-hydroxyvalerate) microparticles 
The PHBV (molecular weight (Mw) = 425,692 g mol-1) (PHB Industrial S.A., Brazil) 
microparticles were prepared by using a modification of the double emulsion solvent 
evaporation method previously described by Ogawa (Ogawa, 1988). The W/O/W double 
emulsion technique was followed since it offers the possibility of incorporating both 
hydrophobic and hydrophilic molecules, allowing the incorporation of several agents 
(Freiberg, 2004). The first step of this method is the formation of water in oil (W1/O) 
emulsion where the aqueous solution (W1) can contain or not the hydrophilic active 
component and the organic phase (O) contains a hydrophobic polymer. In detail, 3 ml of a 
0.5% w/v Poly(vinyl alcohol) (PVA) (Sigma-Aldrich, Germany) aqueous solution (W1) was 
mixed with 15 mL of a 3% w/v PHBV solution in chloroform-ethanol (O). Two different 
ratios of chloroform-ethanol were used in order to verify its effect over the release profile 
of the bioactive substances, namely 100:0 chloroform:ethanol (100 PHBV MPs) and 90:10 
chloroform:ethanol (90 PHBV MPs). The mixture was emulsified for 3 minutes using an 
ultra-turrax T18 (IKA-Werke, Germany) in order to obtain the first emulsion (W1/O). The 
primary emulsion was then dripped into 150 mL of 1% w/v PVA solution (W2) and 
homogenized (RW 16 basic IKA-Werke, Germany) during 5 minutes forming the 
secondary emulsion (W1/O/W2). The final W1/O/W2 emulsion was left to evaporate under 
magnetic stirring for 4–5 h. The obtained microspheres were collected by centrifugation, 
washed at least three times with deionized water and freeze-dried.  
 
3.1. Loading Poly (hydroxybutyrate-co-hydroxyvalerate) microparticles with 
bioactive molecules 
After optimizing the procedure of preparation of PHBV MPs it was proceeded to the 
incorporation of Bovine Serum Albumin (BSA) and Dexamethasone (Dex), respectively as 
protein and hydrophilic bioactive substance model, and glucocorticoid as well as 
hydrophobic molecule model.  
3.1.1. Bovine Serum Albumin-loaded Poly (hydroxybutyrate-co-hydroxyvalerate) 
microparticles 
BSA-loaded PHBV MPs were also prepared following the same protocol previously 
described. In this sense, BSA (Sigma-Aldrich, Germany) was used at a concentration 
0.1% (w/v), being dissolved within the first aqueous phase (W1). 
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3.1.2. Dexamethasone-loaded Poly (hydroxybutyrate-co-hydroxyvalerate) 
microparticles 
A similar procedure described above was followed aiming at incorporate Dex (Sigma-
Aldrich, Germany) within the PHBV microparticles (MPs). Regarding this, Dex was 
dissolved in the organic phase at a final concentration of 3.3x10-3 % (w/v).  
 
4. Gellan Gum hydrogel preparation 
For the preparation of the injectable GG hydrogels the procedure previously described by 
Silva (Silva, 2013) was followed. Gelzan CM (Sigma-Aldrich, Germany) powder was 
mixed at room temperature with deionized water at a concentration of 1.25% (w/v) under 
constant stirring. The solution was heated at 90ºC and kept at this temperature for 30 min. 
Subsequently, CaCl2 (VWR, USA) was added to the GG solution at a concentration of 
0.18% (w/v) to act as a crosslinker. Finally, the solution was left at room temperature 
during approximately one hour, allowing the formation of the gel, which was maintained in 
a phosphate-buffered saline (PBS) solution.  
 
4.1. Incorporation of Poly (hydroxybutyrate-co-hydroxyvalerate) microparticles in 
Gellan Gum hydrogel 
To incorporate PHBV MPs into the GG hydrogel, a similar procedure previously described 
was followed. In this regard, 30 mg of PHBV MPs were dispersed into 20 mL of a 1.25% 
(w/v) GG solution. This solution was posteriorly cross-linked with 0.18% (w/v) of CaCl2 
and left at room temperature during approximately one hour, being maintained in a PBS 
solution. 
 
5. Determination of Particles Production Yield 
The yield of the particles prepared under the different conditions defined in section 3 was 
calculated using Equation 1. 
20 
 
      ( )  
  
  
      (Equation 1) 
The yield was calculated based on the weight of MPs (  ) and compared to the weight of 
the compounds used to prepare the MPs (  ), polymer or the sum of polymer and 
bioactive substance. 
 
6. Efficiency of incorporation of bioactive molecules into the Poly 
(hydroxybutyrate-co-hydroxyvalerate) microparticles 
6.1. Bovine Serum Albumin Quantification 
Aiming at determining BSA incorporation efficiency (IE) into the MPs, 10 mg of BSA-
loaded MPs were completely dissolved in chloroform with vigorous shaking and at room 
temperature for 24 hours. This allows the dissolution of PHBV and at the same time 
permits the release of the entrapped BSA. Then 10 mL of PBS were added in order to 
dissolve the BSA. After centrifugation, the supernatant was collected and filtered through 
0.2 mm membrane. Then, the concentration of incorporated protein was measured using 
a Micro BCATM Protein Assay Kit (Pierce, IL) and measured at 562 nm by Synergy HT 
multi-detection microplate reader (Bio-Tek's Gen5™, USA). This assay is based on two 
chemical reactions. The first is the reduction of cupric ions (Cu+2) to cuprous ions (Cu+1) by 
the peptide bonds, known as the biuret reaction, and by the presence of four amino acids 
(cysteine, cystine, tryptophan and tyrosine) in an alkaline environment (Wiechelman, 
1988; Huang, 2010). The second step is the chelation of one Cu+1 with two bicinchoninic 
acid molecules, which forms an intense purple complex, which has a peak absorbance at 
562nm (Smith, 1985). The protein concentration in a solution is determined by comparing 
this absorbance with a standard curve of absorbance from known concentration of BSA 
varying from 0 – 3.0% (w/v). The IE of BSA within PHBV MPs was calculated by equation 
2, as follows: 
   ( )  
                            
          
     (Equation 2) 
6.2. Dexamethasone Quantification 
PHBV MPs with incorporated Dex were dissolved as described in section 1. Dex 
concentration in the solution was measured at 242 nm by Synergy HT multi-detection 
microplate reader in a 96-well quartz plate (n = 3). The amount of Dex was extrapolated 
21 
 
from a standard curve prepared with Dex solutions with known concentration in a range of 
0 - 3x10-2 % (w/v). The IE of Dex was calculated as follows: 
   ( )  
                            
          
     
(Equation 3) 
 
 
7. In vitro Release Studies 
7.1. In vitro Release Studies from Poly (hydroxybutyrate-co-hydroxyvalerate) 
microparticles 
In vitro release from PHBV MPs of both model bioactive substances was evaluated up to 
21 days. Approximately, 30 mg of MPs were incubated in 10 mL of PBS (0.01 M, pH = 
7.4), and maintained in a precision water bath (Grant, UK) at 60 rpm and 37±0.5ºC. At 
defined time points, ﬁrst at 0, 15, 30 min, and then between 1 and 8 hours, followed by 2, 
3, 4, 5, 7, 14 and 21 days, 1 mL of supernatant was collected and an equivalent amount of 
fresh PBS at 37 ºC was added to maintain the total volume of the sample. The 
concentrations of BSA and Dex in medium were measured at 562 and 242 nm, 
respectively by using the microplate reader.  
7.2. In vitro Release Studies from Poly (hydroxybutyrate-co-hydroxyvalerate) 
microparticles embedded within Gellan Gum hydrogels 
The in vitro release of both bioactive model substances from PHBV MPs embedded within 
GG hydrogels was performed during 21 days. Approximately, 220 µL of GG hydrogel 
embedding PHBV MPs were incubated in 10 mL of PBS (0.01 M, pH = 7.4), and 
maintained in a precision water bath. At defined time points, 1 mL of supernatant was 
collected and an equivalent amount of fresh PBS at 37ºC was added to maintain the total 
volume of the sample. The concentrations of BSA and Dex in medium were measured at 
562 and 242 nm, respectively by using the microplate reader. 
 
8. Laser Diffraction Spectrometry 
The particle size distribution of the prepared MPs was measured by laser diffraction 
spectrometry (Coulter LS 230, Coulter Electronics, USA). The dried samples were 
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suspended in a 0.2% (v/v) of Tween 80 (Sigma-Aldrich, Germany) solution and sonicated 
for 5 min with an ultra-sound probe (Sonoswiss SW 6 H, Sonoswiss® AG, Switzerland) 
before measurement. The obtained homogeneous suspension was used for the particle 
size distribution analysis.  
 
9. Fourier Transform Infrared spectroscopy 
Fourier Transform InfraRed Spectroscopy (FTIR) analyses, under Transmission mode, 
were performed in PHBV microparticles (unloaded, loaded and after release) in order to 
analyse their chemical composition. With this purpose, 1 mg of microparticles were mixed 
with 40 mg of Potassium Bromide (KBr) and then processed into a disc in a manual press 
(161-1100 hand press, Pike technologies, Madison, WI). FTIR-KBr spectra (IR Prestige 
21, Shimadzu, Japan) were recorded at 40 scans with a resolution of 4 cm-1, at 
wavelengths from 1400 to 4000 cm-1. 
 
 
10. Scanning Electron Microscopy 
The morphology of the PHBV MPs and dehydrated PHBV MPs embedded within GG 
hydrogels was analysed before and after the in vitro release studies, by scanning electron 
microscopy (SEM) using a model S360 microscope (Leica Cambridge, UK). Moreover, the 
cross sections of the microparticles were performed after the embedding of this particulate 
system within the GG hydrogel which were submitted to several cuts. Before being 
analysed, the different structures were gold sputter coated (model SC502; Fisons 
instruments, UK) for 2 minutes at 15 mA. Micrographs were recorded at 5.0 kV with 
magnifications of 250, 1 000, 2 000, 8 000 and 20 000. 
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Abstract 
Design and synthesis of efficient drug delivery systems (DDS) are of vital importance for tissue 
engineering and regenerative medicine (TERM). With a view toward developing DDS to be applied 
using minimally-invasive approaches, and that would provide sustained, prolonged and localized 
release of biochemical cues relevant for tissue regeneration, we designed a biphasic injectable 
DDS combining Polyhydroxybutyrate-co-hydroxyvalerate (PHBV) microparticles (MPs) within a 
gellan gum (GG) hydrogel. 
Model molecules of proteins, Bovine Serum Albumin (BSA), and glucocorticoids, Dexamethasone 
(Dex), were incorporated inside PHBV MPs by using a double emulsification-solvent evaporation 
method with modifications. Aiming at tailoring the bioactive molecules release profile, different 
proportions of chloroform and ethanol, as organic phase, were proposed. This modification 
revealed to affect some features of the microparticulate system, namely particle size and surface 
topography. The presence of ethanol led to higher efficiency of Dex entrapment inside the MPs, 
from 82 to 92 %, approximately, but did not affect BSA incorporation, approximately 66% 
independently of the presence of ethanol. 
In his turn, the in vitro release studies revealed that MPs produced in the absence of ethanol in the 
organic phase presented a more sustained profile when compared to the MPs produced in the 
presence of ethanol. This finding was expected since the addition of ethanol to the organic phase 
induced the formation of larger pores on the surface and in the core of the MPs thus facilitating 
water penetration, and consequently faster release of the bioactive molecule. 
In his turn, the in vitro release results indicated that around 68% of Dex incorporated in the MPS 
produced in the absence of ethanol was released after 21 days, while from the particulate system 
produced in the presence of ethanol 100% of the incorporated Dex was released after 5 days. 
Regarding BSA, the presence of ethanol during MPs fabrication did not affect the amount of protein 
released after 21 days of immersion, around 78% independently of the conditions. In order to 
define a system that would act as carrier of the MPs enhancing MPs residence time upon injection, 
the obtained PHBV MPs were embedded within injectable GG hydrogels. As expected, the 
incorporation of the MPs into the GG hydrogels strongly influenced the profile, from one to nearly 
zero-order and the amount of released Dex and BSA. However, a uniform distribution of PHBV 
MPs across the GG matrix with a strong integration of the MPS was attained. 
In this sense, a biphasic DDS, which allows the release of biochemical cues with different 
physicochemical features, as well as its localized deliver, was successfully developed and 
represents a versatile tool to prepare instructive cell microenvironments for TERM.  
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1. Introduction 
Design and synthesis of efficient drug delivery systems (DDS) are of vital importance for 
tissue engineering (TE) and regenerative medicine (RM) applications (Biondi, 2008) as a 
way to maintain a particular active agent’s concentration in patients’ blood and/or tissues 
for an extended time, without the need of additional administration (Amass, 1998; Kost, 
2001). So far, these systems have been relying on liposomes (Drulis-Kawa, 2010; 
Monteiro, 2013), micelles (Wilson, 2013; Xu, 2013), polymeric micro and nanoparticles 
(Joshi, 2013; Liang, 2013; Kozielski, 2013; Wang, 2013), cyclodextrins (Chen, 2011; 
Dhule, 2012), among others (Oliveira, 2011). Drug carriers for implantable or injectable 
DDS should have good biocompatibility, biodegradability and controlled drug 
delivery/release capability.  
Biodegradable polymers, either synthetic or natural, are capable of being cleaved into 
biocompatible byproducts through chemical or enzyme-catalyzed hydrolysis. This 
biodegradable property makes it possible to implant them into the body with predicted 
release profile and without the need of subsequent removal by surgical operation. Drugs 
formulated with these polymers can be released in a controlled manner, by which the drug 
concentration in the target site is maintained within the therapeutic window. The release 
rates of the drugs from biodegradable polymers can be controlled by a number of factors, 
such as biodegradation kinetics of the polymers (Ciçek, 1995; Zhang, 2002; Mi, 2002), 
physicochemical properties of the polymers and drugs (Calandrelli, 2002; Abraham, 
2003), thermodynamic compatibility between the polymers and drugs (Liu, 2004), and the 
shape of the devices (Chen, 2001; Tunón, 2003; Fulzele, 2004). 
Several based biodegradable polymers have been used for this purpose, including 
poly(lactide-co-glycolide) (Wen, 2013), poly(l-lactic acid) (Correia, 2013), chitosan 
(Champa, 2010), alginate (Iwanaga, 2013), starch-poly-ε-caprolactone (Balmayor, 2009), 
poly(hydroxybutyrate) (PHB) (Shishatskaya, 2008) and poly(hydroxybutyrate-co-
hydroxyvalerate) (PHBV) (Chen, 2012).  
Polyhydroxyalkanoates (PHAs) have been intensively investigated as a family of natural 
biodegradable and biocompatible materials for in vivo applications as implantable TE 
material, as well as, release vectors for various drugs (Kabilan, 2012). PHAs have 
physicochemical properties similar to the widely used synthetic polymers (e.g. propylene 
and polyethylene), which are non-biodegradable being most of the time compared with 
poly(lactide-co-glycolide), a biodegradable synthetic polymer. PHAs are produced by a 
wide variety of microorganisms as an internal carbon and energy storage, as part of their 
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survival mechanism (Doi, 2002; Jung, 2005). In fact, in vivo studies revealed that PHB 
and PHBV, which are members of PHAs family, degrade into d-3-hydroxybutyrate acid, 
which is a normal constituent of human blood, which my justify the low toxicity of PHB 
(Tokiwa, 2004; Choi, 2005; Cheng, 2006). PHBV is thermoplastic optically active polyester 
which is insoluble in water and exhibit a high degree of polymerization (Scandola, 1997; 
Kang, 2001). This polymer presents some interesting characteristics, namely antioxidant 
(i.e. inhibits the oxidation of other molecules) and piezoelectric properties, i.e. the capacity 
of a material to suffer electric polarization due to mechanical stress (Chen, 2000). 
Moreover, PHA have various chemical compositions and functionalized groups in the side 
chain that allows further chemical modification, which is a major advantage in DDS 
development, since it allows to tailor its degradation according with the pretended 
application (Wu, 2009; Chen, 2013). 
There are several techniques regarding the development of microparticulate systems, 
including W/O/W double emulsion, organic phase separation, supercritical fluid, and spray 
drying techniques. Among them, the W/O/W double emulsion technique is a well-used 
process, which offers the possibility of incorporating both hydrophilic and hydrophobic 
molecules, allowing the incorporation of several agents (Freiberg, 2004).  
One of aim of the current study concerned the development of microparticles (MPs) made 
up of PHBV, a PHB copolymer which presents less crystalline and more flexible, and for 
being used as carriers of dexamethasone (Dex) and bovine serum albumin (BSA), 
hydrophobic and hydrophilic model drugs, respectively. For this purpose, it was adopted a 
water-in-oil-in-water double emulsion solvent evaporation technique, since as previously 
mentioned allow the incorporation of water-soluble molecules. The propose method was 
previously modified aiming to tailor the delivery of the bioactive agents aiming to 
regenerate a defined tissue accordingly with its needs. In this sense, for the production of 
PHBV MPs a mixture of different solvents was used in different proportions, namely 100:0 
% (v/v) chloroform:ethanol and 90:10%(v/v) chloroform:ethanol. This strategy was 
proposed by Poletto and co-workers aiming the control over PHBV particles size using an 
emulsification-diffusion technique, and subsequently effect on the bioactive substance 
release profile (Poletto, 2008). 
When MPs are injected in target tissues, they are continuously exposed to external 
mechanical deformation, leading to the uncontrollable displacements of particles 
(Fitzgerald, 1987; Griffith, 2000; Chan, 2005). This displacement greatly affects the 
concentration of bioactive macromolecules in target tissues, resulting in limited tissue 
regeneration (Lemperle, 2004). Moreover, when in free movement the particulate system 
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can be expelled even before release of the therapeutic agent. Therefore, extensive efforts 
are being made to resolve this challenge while harnessing the advantages of particulate 
systems, including their minimally invasive and controllable drug delivery.  
Herein, we propose an innovative delivery system composed of MPs embedded into a 
hydrogel that enables the control over release kinetics from simultaneous, combined and 
sequential delivery of different biochemical cues in a predefined spatiotemporal manner. 
In this sense, the microparticulate system loading bioactive molecules would be combined 
with injectable Gellan Gum (GG) hydrogels. Injectable GG hydrogels have been shown to 
be a suitable platform to support and deliver cells for noninvasive injectable TE 
applications (Oliveira, 2010). With this in mind, a hybrid structure was produce aiming the 
co-localization of MPs spatial distribution and consequently the release site, as well as, 
producing a long term release that can expedite tissue regenerative processes. In this 
sense, BSA and Dex were used as bioactive molecules models; in this way we herein 
describe a new approach that allows not only the incorporation and further release of both 
relevant bioactive hydrophilic and hydrophobic molecules, as well as their incorporation in 
an injectable platform. 
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2. Materials and Methods 
2.1. Preparation of Poly (hydroxybutyrate-co-hydroxyvalerate) microparticles 
The PHBV (molecular weight (Mw) = 425,692 g mol-1) (PHB Industrial S.A., Brazil) MPs 
were prepared by using a modification of the double emulsion solvent evaporation method 
previously described by Ogawa (Ogawa, 1988). Briefly, 3 ml of a 0.5% w/v Poly(vinyl 
alcohol) (PVA) (Sigma-Aldrich, Germany) aqueous solution (W1) was mixed with 15 mL of 
a 3% w/v PHBV solution in chloroform-ethanol (O). Two different ratios of chloroform-
ethanol were used in order to verify its effect over the release profile of the bioactive 
substances, namely 100:0 chloroform:ethanol (100 PHBV MPs) and 90:10 
chloroform:ethanol (90 PHBV MPs).The mixture was emulsified for 3 minutes using an 
ultra-turrax T18 (IKA-Werke, Germany) in order to obtain the first emulsion (W1/O). The 
primary emulsion was then dripped into 150 mL of 1% (w/v) PVA solution (W2) and 
homogenized (RW 16 basic IKA-Werke, Germany) during 5 minutes forming the 
secondary emulsion (W1/O/W2). The final W1/O/W2 emulsion was left to evaporate under 
magnetic stirring for 4–5 h. The obtained microspheres were collected by centrifugation, 
washed at least three times with deionized water and freeze-dried.  
2.1.1. Bovine Serum Albumin-loaded Poly (hydroxybutyrate-co-hydroxyvalerate) 
microparticles 
BSA-loaded PHBV MPs were also prepared following the same protocol previously 
described. In this sense, BSA (Sigma-Aldrich, Germany) was used at a concentration 
0.1% (w/v), being dissolved within the first aqueous phase (W1). 
2.1.2. Dexamethasone-loaded Poly (hydroxybutyrate-co-hydroxyvalerate) 
microparticles 
A similar procedure described above was followed aiming at incorporate Dex (Sigma-
Aldrich, Germany) within the PHBV MPs. Regarding this, Dex was dissolved in the 
organic phase at a final concentration of 3.3x10-3 % (w/v).  
 
2.2. Gellan Gum hydrogel preparation 
For the preparation of the injectable GG hydrogels the procedure previously described by 
Silva (Silva, 2013) was followed. Gelzan CM (Sigma-Aldrich, Germany) powder was 
mixed at room temperature with deionized water at a concentration of 1.25% (w/v) under 
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constant stirring. The solution was heated at 90ºC and kept at this temperature for 30 min. 
Subsequently, CaCl2 (VWR, USA) was added to the GG solution at a concentration of 
0.18% (w/v) to act as a crosslinker. Finally, the solution was left at room temperature 
during approximately one hour, allowing the formation of the gel, which was maintained in 
a phosphate-buffered saline (PBS) solution.  
2.2.1. Incorporation of Poly (hydroxybutyrate-co-hydroxyvalerate) microparticles in 
Gellan Gum hydrogel 
To incorporate PHBV MPs into the GG hydrogel, a similar procedure previously described 
was followed. In this regard, 30 mg of PHBV MPs were dispersed into 20 mL of a 1.25% 
(w/v) GG solution. This solution was then cross-linked with 0.18% (w/v) of CaCl2 and left 
at room temperature during approximately one hour, being maintained in a PBS solution. 
 
2.3. Determination of Particles Production Yield 
The yield of the particles prepared under the different conditions defined in section 3 was 
calculated using Equation 1. 
      ( )  
  
  
      (Equation 1) 
The yield was calculated based on the weight of MPs (  ) and compared to the weight of 
the compounds used to prepare the MPs (  ), polymer or the sum of polymer and 
bioactive substance. 
 
2.4. Efficiency of incorporation of bioactive molecules into the Poly 
(hydroxybutyrate-co-hydroxyvalerate) microparticles 
2.4.1. Bovine Serum Albumin Quantification 
Aiming at determining BSA IE into the MPs, 10 mg of BSA-loaded MPs were completely 
dissolved in chloroform with vigorous shaking and at room temperature for 24 hours. This 
allows the dissolution of PHBV and at the same time permits the release of the entrapped 
BSA. Then 10 mL of PBS were added in order to dissolve the BSA. After centrifugation, 
the supernatant was collected and filtered through 0.2 mm membrane. Then, the 
concentration of incorporated protein was measured using a Micro BCATM Protein Assay 
31 
 
Kit (Pierce, IL) and measured at 562 nm by Synergy HT multi-detection microplate reader 
(Bio-Tek's Gen5™, USA). The IE of BSA within PHBV MPs was calculated by equation 2, 
as follows: 
   ( )  
                            
          
     (Equation 2) 
 
2.4.2. Dexamethasone Quantification 
PHBV MPs and incorporated Dex were dissolved as described in section 1. Dex 
concentration in the solution was measured at 242 nm by Synergy HT multi-detection 
microplate reader in a 96-well quartz plate (n = 3). The incorporation efficiency (IE) of Dex 
was calculated as follows: 
   ( )  
                            
          
     
(Equation 3) 
 
 
2.5. In vitro Release Studies 
2.5.1. In vitro Release Studies from Poly (hydroxybutyrate-co-hydroxyvalerate) 
microparticles 
In vitro release from PHBV microspheres of both model bioactive substances was 
evaluated up to 21 days. Approximately, 30 mg of microspheres were incubated in 10 mL 
of PBS (0.01 M, pH = 7.4), and maintained in a precision water bath (Grant, UK) at 60 rpm 
and 37±0.5ºC. At defined time points, 1 mL of supernatant was collected and an 
equivalent amount of fresh PBS at 37ºC was added to maintain the total volume of the 
sample. The concentrations of BSA and Dex in medium were measured at 562 and 242 
nm, respectively by using the microplate reader.  
2.5.2. In vitro Release Studies from Poly (hydroxybutyrate-co-hydroxyvalerate) 
microparticles embedded within Gellan Gum hydrogels 
The in vitro release of both bioactive model substances from PHBV MPs embedded within 
GG hydrogels was performed during 21 days. Approximately, 220 µL of GG hydrogel 
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embedding PHBV MPs were incubated with 10 mL of PBS (0.01 M, pH = 7.4), and 
maintained in a precision water bath at 60 rpm and 37±0.5ºC. At defined time points, 1 mL 
of supernatant was collected and an equivalent amount of fresh PBS at 37ºC was added 
to maintain the total volume of the sample. The concentrations of BSA and Dex in medium 
were measured at 562 and 242 nm, respectively by using the microplate reader. 
 
2.6. Laser Diffraction Spectrometry 
The particle size distribution of the prepared MPs was measured by laser diffraction 
spectrometry (Coulter LS 230, Coulter Electronics, USA). The dried samples were 
suspended in a 0.2% Tween 80 (Sigma-Aldrich, Germany) solution and sonicated for 5 
min with an ultra-sound probe (Sonoswiss SW 6 H, Sonoswiss® AG, Switzerland) before 
measurement. The obtained homogeneous suspension was used for the particle size 
distribution analysis.  
 
2.7. Fourier Transform Infrared spectroscopy 
Fourier Transform InfraRed Spectroscopy (FTIR) analyses, under Transmission mode, 
were performed in PHBV MPs (unloaded, loaded and after release) in order to analyse 
their chemical composition. With this purpose, 1 mg of MPs were mixed with 40 mg of 
Potassium Bromide (KBr) and then processed into a disc in a manual press (161-1100 
hand press, Pike technologies, Madison, WI). FTIR-KBr spectra (IR Prestige 21, 
Shimadzu, Japan) were recorded at 40 scans with a resolution of 4 cm-1, at wavelengths 
from 1400 to 4000 cm-1. 
 
2.8. Scanning Electron Microscopy  
The morphology of the PHBV MPs and dehydrated PHBV MPs embedded within GG 
hydrogels was analysed before and after the in vitro release studies, by scanning electron 
microscopy using a model S360 microscope (Leica Cambridge, UK). Moreover, the cross 
sections of the MPs were performed after the embedding of this particulate system within 
the GG hydrogel which were submitted to several cuts. Before being analysed, the 
different structures were gold sputter coated (model SC502; Fisons instruments, UK) for 2 
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minutes at 15 mA. Micrographs were recorded at 5.0 kV with magnifications of 250, 1 000, 
2 000, 8 000 and 20 000. 
 
3. Results  
3.1. Poly (hydroxybutyrate–co–hydroxyvalerate) microparticles Process Production 
The PHBV MPs were produced following a double emulsion solvent evaporation method 
(Figure 1). The propose method was previously modified with the objective of tailoring the 
delivery of relevant biochemical cues aiming to regenerate a defined tissue accordingly 
with its needs. In this sense, for the production of PHBV MPs a mixture of different 
solvents was used in different proportions, namely 100:0 (v/v) chloroform:ethanol and 
90:10 (v/v) chloroform:ethanol. 
 
Figure 1 – Schematic depiction of double emulsification evaporation method. 
After the preparation of PHBV MPs, the process yield was calculated for the particles 
obtained under different conditions aiming to assess its reproducibility, as well as, the 
potential effect of the tested conditions (Table I). The results showed that when ethanol 
was added to the process, yield decreased 6%.  
Table I. Yield and Size of the PHBV MPs produced under different conditions. 
Processing Conditions 
Chloroform:Ethanol ratio 
Yield, %  
(mean ±SD) 
Particle Size 
Distribution, µm 
(mean ±SD) 
PHBV (100:0) 95.7 ±2.32 41.9 ±20.2 
PHBV (90:10) 90.3 ±2.43 57.6 ±29.1 
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The size distributions of the MPs obtained using different proportions of 
chloroform/ethanol in the organic phase for the first emulsification was further determined 
and the results are shown in Table I. PHBV MPs prepared exclusively with chloroform 
showed a mean particle size range of 15.6 to 76.4 µm, whilst the particles obtained using 
ethanol present a particle size range of 5.6 to 91.1 (Figure 2). 
 
Figure 2 – Particle size distribution of the PHBV MPs. 
The mean particle size of unloaded-MPs obtained by adding ethanol to the process was 
found to be larger than MPs where it was exclusively used chloroform.  
The morphology of the produced MPs was analysed by SEM (Figure 3). Perfect spherical 
shape MPs of different sizes were observed (Figure 3 A1 and B1) which is in accordance 
with the measured particle size distribution (Table I). Moreover, a detailed analysis of MPs 
surface topography revealed rough surfaces with the presence of some micro-size pores 
(Figure 3 A3 and B3). The presence of this porosity is not dependent on the microsphere 
preparation conditions, although, the addition of ethanol leads to a different surface 
topography. 
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Figure 3 - SEM micrographs of PHBV MPs obtained under different experimental conditions: (A) 
using 100% chloroform; and (B) a mixture of 90% chloroform: 10% ethanol. The sequential 
micrographs represent an overview of the obtained MPs showing the detail of their surface and 
respective close up of the internal morphology. 
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Like for the external porosity, independently of the processing conditions used, the 
produced MPs presented a porous core (Figure 3A4 and B4). Nonetheless, the addition of 
ethanol to the organic phase leads to the formation of larger pore (Figure 3B4).  
 
3.2. Bovine Serum Albumin and Dexamethasone Entrapment Efficiency and Release 
Profile 
3.2.1. Loaded Microparticles properties 
The impact of the incorporation of bioactive substances within PHBV MPs on the process 
yield and particle size was further determined (Table II). 
Table II. Yield and Size of the PHBV loaded MPs produced under different conditions. 
Processing Conditions 
Chloroform:Ethanol ratio 
Yield, % 
(mean ±SD) 
 
Particle Size Distribution, µm 
(mean ±SD) 
Entrapped bioactive 
molecule 
Dex BSA Dex BSA 
PHBV (100:0) 95.4 ±1.36 88.8 ±5.50 55.0 ±39.4 78.5 ±78.5 
PHBV (90:10) 89.9 ±5.64 79.0 ±9.83 58.3 ±27.5 63.0 ±42.2 
Regarding the process yield results, no significant differences were observed between the 
unloaded-PHBV MPs (Table I) and Dex-loaded MPs (Table II). However, the results also 
showed that BSA-loaded MPs presented a lower yield than the unloaded-MPs. 
In what concerns the particle size of the PHBV-loaded MPs, the incorporation of the 
bioactive molecules lead to an increased size, with the exception of Dex in the presence 
of ethanol (Table II). Furthermore, increase in size of MPs was found to be proportional to 
the molecular weight of the bioactive substance that was incorporated. Thus, the MPs 
loaded with Dex (392.46 Da) exhibited a reduced mean particle size when compared with 
the MPs loaded with BSA (approx. 66 kDa) (Table II). 
The SEM analysis of the loaded-PHBV MPs confirmed not only the particles size 
measurements but also the maintenance of the spherical morphology after incorporation 
of the bioactive molecules (Figure 4A1 and B1). Despite, the morphology of the loaded 
MPs surface was similar to the surface of the unloaded-PHBV MPs produced in the 
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absence of ethanol (Figure 3A3). These observations were independent of the 
incorporated molecule (Figure 4A2 and B2). 
 
 
 
 
 
 
 
 
 
Figure 4 - SEM micrographs of BSA loaded-PHBV MPs obtained under different experimental 
conditions: (A) using 100% chloroform; and (B) 90% chloroform: 10% ethanol. The sequential 
micrographs represent an overview of the obtained MPs showing the detail of their surface. 
The incorporation efficiency of BSA and Dex within the PHBV MPs obtained under 
different experimental conditions are described in Table III. 
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Table III. Incorporation Efficiency of Bovine Serum Albumin and Dexamethasone within PHBV 
MPs. 
Processing Conditions 
Chloroform:Ethanol ratio 
Incorporation Efficiency, % 
(mean ±SD) 
 
Dex BSA 
PHBV (100:0) 81.6 ±8.41 66.2 ±3.33 
PHBV (90:10) 92.3 ±2.17 65.5 ±1.72 
 
The entrapment efficiency results of BSA inside PHBV MPs revealed no significant 
differences when ethanol was added to the organic phase and efficiency around 66% was 
achieved independently of the processing conditions (Table III). 
Regarding the incorporation efficiency of Dex, it was found to be 81.6 ±8.41% in the 
absence of ethanol on the organic phase, while the other was 92.3 ±2.17%. Thus, the 
bioactive molecule entrapment efficiency was affected by organic phase composition. 
The entrapment of BSA within PHBV MPs was further confirmed by FTIR analysis (Figure 
5). The FTIR spectra of BSA-loaded PHBV MPs revealed the BSA’ characteristic bands 
for both formulations, indicating that the hydrophilic drug was successfully incorporated 
within the PHBV MPs.  
 
Figure 5 – FTIR spectra of BSA and PHBV MPs: BSA (black line); 100 unloaded-PHBV MPs (red 
line); 90 unloaded-PHBV MPs (blue line); 100 BSA-loaded PHBV MPs (pink line); 90 BSA-loaded 
PHBV MPs (green line). The characteristics bands of BSA are marked (*). 
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FTIR analysis was also performed aiming to confirm the Dex entrapment inside PHBV 
MPs (Figure 6). The FTIR spectra of Dex-loaded PHBV MPs showed its characteristics 
bands, indicating the effectiveness of the entrapment procedure of Dex inside the MPs 
obtained by using different organic phase compositions. 
 
Figure 6 – FTIR spectra of Dex and PHBV MPs: Dex (black line); 100 unloaded-PHBV MPs (red 
line); 90 unloaded-PHBV MPs (blue line); 100 Dex-loaded PHBV MPs (pink line); 90 Dex-loaded 
PHBV MPs (green line). The characteristics bands of Dex are marked (*). 
 
3.2.2. Bovine Serum Albumin Release from Poly (hydroxybutyrate–co–
hydroxyvalerate) microparticles 
The release profile of BSA from BSA-loaded PHBV MPs obtained under different 
conditions and up to 21 days is shown in Figure 7. The results of the MPs produced in the  
absence of ethanol indicate that 76% of BSA was released within the first 8 hours of 
incubation reaching a release of approximately 78% of the incorporated BSA at day 21. In 
contrast, the BSA loaded-MPs produced with a mixture of chloroform and ethanol, as 
organic phase, released about 78% of the incorporated BSA within the first 8 hours. After 
21 days of incubation, approximately 80% of BSA was released from BSA-loaded PHBV 
MPs. 
The BSA release profiles were confirmed by FTIR analysis (Figure 8). After the release 
studies, the FTIR spectra of BSA-loaded 100 PHBV MPs, in which the organic phase 
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does not contain ethanol, revealed a reduction in the intensity of the BSA characteristic 
bands (Figure 8 – dark blue line). However, it is evident the presence of the typical peaks 
of BSA even after 21 days of incubation from BSA-loaded 100 PHBV MPs.  
 
Figure 7 - In vitro release profile of BSA from BSA-loaded PHBV MPs obtained using a mixture of 
chloroform and ethanol in different proportions: (100:0) % ( ); and (90:10) % ( ). 
 
Figure 8 – FTIR spectra of BSA-loaded PHBV MPs: BSA-loaded 100 PHBV MPs (black line) and 
BSA-loaded 90 PHBV MPs (red line) before release studies; and BSA-loaded 100 MPs (blue line) 
and BSA-loaded 90 MPs (purple line) after 21 days of in vitro release. The characteristics bands of 
BSA are marked (*). 
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The degradation of the MPs incorporating both hydrophobic and hydrophilic bioactive 
substances (BSA and Dex) was monitored by SEM. As shown in Figure 9, there are 
slightly morphological and topographical differences after the in vitro release studies. 
However, is possible to observe for almost all the formulations that the microparticulate 
systems maintain their structure and integrity.  
 
 
 
  
   
Figure 9 - SEM micrographs of BSA-loaded PHBV MPs obtained under different experimental 
conditions: (A) using 100 % chloroform; and (B) with 90% chloroform: 10% ethanol, after 21 days of 
in vitro release studies. The sequential micrographs represent an overview of the obtained MPs 
showing the detail of their surface. 
 
3.2.3. Dexamethasone Release from Poly (hydroxybutyrate–co–hydroxyvalerate) 
microparticles 
The release of Dex from Dex-loaded PHBV MPs obtained under different conditions and 
up to 21 days is shown in Figure 10. The results from the Dex loaded-100 PHBV MPs 
produced in the absence of ethanol indicate that 55% of Dex was released within the first 
8 hours of incubation reaching a release of approximately 69% of the incorporated Dex at 
day 21. In opposition, the Dex loaded-MPs produced with a mixture of chloroform and 
ethanol as organic phase released about 89% of the incorporated Dex within the first 8 
hours and no Dex was left in the MPs after 5 days of incubation. 
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The Dex release profiles were confirmed by FTIR analysis (Figure 11). The FTIR spectra 
of Dex-loaded 90 PHBV MPs after the release studies revealed a reduction in the intensity 
of the Dex characteristic bands in the IR spectrum of the Dex-loaded PHBV MPs wherein 
the organic phase consists only of chloroform (Figure 11 – dark blue line) and the 
absence of those bands for the Dex loaded-100 PHBV MPs. 
 
Figure 10 - In vitro release profile of Dex loaded-MPs obtained using a mixture of chloroform and 
ethanol in different proportions: (100:0) % ( ); and (90:10) % ( ). 
 
Figure 11 – FTIR spectra of Dex-loaded PHBV MPs: Dex-loaded 100 PHBV MPs (black line) and 
Dex-loaded 90 PHBV MPs (red line) before release studies; and 100 Dex-loaded MPs (line) and 90 
Dex-loaded MPs (purple line) after 21 days of in vitro release. The characteristics bands of Dex are 
marked (*). 
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3.3. Injectable Gellan Gum/ Poly (hydroxybutyrate–co–hydroxyvalerate) 
microparticles System  
3.3.1. Injectable System Properties 
The main goal of this work is to propose a stable DDS based on the obtained PHBV MPs. 
For this purpose, the different PHBV MPs were embedded within the GG’ solution prior 
gelation.  
 
Figure 12 – Schematic representation of injectable fluorescein isothiocyanate labelled bovine 
serum albumin – loaded PHBV MPs embedded within GG hydrogel system. 
The SEM analysis of the system after gelation confirmed the homogeneous dispersion of 
the MPs with the hydrogel without losing their spherical shape (Figure 13). 
 
   
Figure 13 - SEM micrographs of PHBV MPs embedded within injectable GG hydrogels. The 
sequential images represent an overview of the distribution of the particles within the hydrogel, 
close up on the surface of the biphasic structure, and a cross-section. 
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Moreover, PHBV-MPs were completely embedded with the GG matrix guaranteeing its 
delivery as a stable combined system. 
 
3.3.2. Bovine Serum Albumin Release from the Injectable Gellan Gum/ Poly 
(hydroxybutyrate–co–hydroxyvalerate) microparticles System 
In order to assess the impact of the incorporation of the MPs within the hydrogel over BSA 
release profile, release studies under the conditions defined for the single MPs were 
carried out (Figure 14). 
 
Figure 14 - In vitro release profile of BSA from GG hydrogels embedding PHBV MPs obtained 
using a mixture of chloroform and ethanol in different proportions: (100:0) % ( ); and (90:10) % (
). 
The release profile confirmed that the presence of the GG hydrogel surrounding the MPs 
reduced significantly the initial burst effect. The results of the MPs produced in the 
absence of ethanol embedded within GG hydrogel indicate that 35% of BSA was released 
within the first 8 hours of incubation reaching a release of approximately 36% of the 
incorporated BSA at day 21. In contrast, the BSA loaded-MPs produced with a mixture of 
chloroform and ethanol as organic phase combined with the GG matrix released about 
40% of the incorporated BSA within the first 8 hours and after 21 days of incubation 
approximately 41% of BSA was released from this system.  
After 21 days of immersion in PBS the system remained stable in the sense that PHBV 
MPs were still embedded in the system (Figure 15). Nonetheless, the hydrogel revealed 
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some signs of degradation, the surface erosion was apparent causing the formation of 
some cavities and suggesting the loss of particles into the medium (Figure 15A2). 
   
Figure 15 - SEM photographs of BSA loaded-MPs embedded within GG hydrogel, after 21 days of 
in vitro release studies. The sequential images represent an overview of the distribution of the 
particles within the hydrogel, close up on the surface of the biphasic structure, and a cross-section. 
 
 
3.3.3. Dexamethasone Release from the Injectable Gellan Gum/Poly 
(hydroxybutyrate–co–hydroxyvalerate) microparticles System 
Regarding the Dex-loaded PHBV MPs embedded within GG hydrogels, the effect of the 
GG matrix on the release profile was evaluated under release studies up to 21 days 
(Figure 16). 
 
Figure 16 - In vitro release of Dex from GG hydrogels embedding PHBV MPs obtained using a 
mixture of chloroform and ethanol in different proportions: (100:0) % (     ); and (90:10) % (    ). 
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The release profile confirmed that GG hydrogel surrounding the MPs eliminated the initial 
burst. Dex release from MPs entrapped into the GG hydrogel showed a nearly zero-order 
release profile. Moreover, Dex was not dependent on the MPs processing conditions as 
no differences were observed between the systems produced in the presence and in the 
absence of ethanol. Both systems attained a release of around 26% at the end of 21 days 
of incubation in PBS. 
 
4. Discussion 
From the clinical point of view, injectable hydrogels formed by in situ polymerization are 
highly desirable since they gain advantages over preformed hydrogels: (1) enabling 
minimally invasive surgeries for implantation; (2) formation in any desired shape in good 
alignment with surrounding tissue defects; and (3) easy encapsulation of bioactive 
molecules and cells (Jin, 2012). With a view toward developing a minimally-invasive DDS 
that would provide sustained local release of biochemical cues, we designed a biphasic 
injectable DDS to be applicable as a long term release system with two distinct objectives: 
i) the control over release profile of proteins and/or glucocorticoids and ii) the spatial 
distribution of the particles avoiding its uncontrolled migration through the human body. 
For this purpose, BSA- and Dex-loaded PHBV MPs, processed by a double 
emulsification-solvent evaporation method with modifications, were incorporated into 
injectable GG hydrogels. In the future, this system will allow overcoming the 
uncontrollable displacements, as well as, the clearance of particles by the organism. 
In this study, PHBV a biodegradable thermoplastic polymer was chosen due to its singular 
properties, namely biocompatibility, low toxicity, and slow degradation. In his turn, GG was 
used because of its stability, biocompatibility and biodegradability. BSA and Dex were 
respectively used as hydrophilic/proteins and hydrophobic/glucocorticoids model 
molecules envisioning the possibility of a combined localized administration of an anti-
inflammatory agent and a cytokine or growth factor by controlled release where high local 
concentrations are needed and/or local concentration gradients need to be established for 
successful tissue regeneration (Chen, 2010). 
While developing microparticulate DDS there are several aspects that are critical since it 
is a complex procedure that involves several processing and design variables. Even 
slightly changes of variables and system components can have significant impact on 
unique features of MPs including particle size and morphology, as well as entrapment 
efficiency of the molecules of interest. The double emulsion solvent evaporation method 
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described by Ogawa et al. (1988), is a highly reproducible method that has been 
extensively used to create particles with a spherical structure and inner core-shell 
structure. MPs of PHBV have been previously produced by this methodology (Li, 2009). 
However, in order to optimize the reported methodology aiming to tailor the bioactive 
molecules release profile, a mixture of different solvents, as organic phase, is herein 
proposed. Chloroform was selected as the solvent for the PHBV and ethanol to improve 
the mutual solubility of the organic and the aqueous phases and based on the type of 
molecular interactions between the organic solvents (dipole-dipole) and between ethanol 
and water (hydrogen bond) (Poletto, 2008).  
The appropriate size of MPs is an important parameter that affects the release behaviour 
of the bioactive substances. The produced PHBV MPs showed a mean particle size 
varying from 41.9 to 78.5 µm, which was affected by the processing conditions, presence 
of ethanol, as well as by the type of bioactive molecule incorporated. The size of the MPs 
in the presence of ethanol was higher than when only chloroform was used as organic 
phase. These results are not in accordance to what was previously reported by Poletto 
(2008) that showed a decrease in the size of PHBV nanoparticles when ethanol was used 
as a surface agent. The distinct results are probably due to the differences between both 
methods used to produce the particles; while they followed an emulsification-diffusion 
technique, the double emulsion solvent evaporation method herein proposed involves 
intense high–speed homogenization, proved to have a tremendous effect on the particle 
size (Mukherjee, 2008). Additionally, it is important to note that the diameters of these 
MPs are less than 100 µm, and thus can be readily injected into the body with comparable 
less pain (Mathew, 2007; Wang, 2007). 
The effect of employing a binary mixture of solvents as organic phase was also 
investigated in terms of morphology. The MPs showed a well-defined spherical shape 
without visual defects, independently of the processing conditions showing a considered 
particle size variation, which is in accordance with the particle size distribution results 
already reported. When employed emulsion/solvent evaporation method, the roughness 
pattern on the microspheres surface has been associated to the high crystallinity and fast 
precipitation of this polymer, after solvent evaporation from the internal phase of the 
emulsion (Bidone, 2009). However, the comparison of the results revealed that the 
surface topographies were also influenced by the addition of ethanol to the process. 
Moreover, the presence of micro-size pores on PHBV microspheres surfaces, 
independently of the microsphere preparation conditions, was observed. The pores could 
help to accelerate the release of the bioactive molecules from the microspheres. 
Additionally, both particulate system obtained under different experimental conditions 
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possess highly porous internal structure, however the addition of ethanol on the organic 
phase lead to larger core pores. This could be attributed to the hydrophobicity of PHBV; 
during the first emulsification process, water droplets (first aqueous phase) can interact 
with the ethanol present in the organic phase, the same is not observed when the organic 
phase is composed only by chloroform, leading to the formation of larger droplets inside 
the dispersed phase and consequently to larger the pores after removal of the water 
droplets by freeze-drying (Zhu, 2007).  
In addition to the processing conditions, the incorporation of BSA and Dex within the 
PHBV MPs also affected the properties of the produced MPs. An increase in mean size 
was observed for the PHBV loaded MPs, which was proportional to the molecular weight 
of the incorporated bioactive molecule. The BSA-loaded MPs (BSA has a MW of 66 kDa) 
exhibited a larger mean size in comparison to Dex-loaded MPs (Dex has a MW of 392.46 
Da). Studies about the inner distribution of hydrophilic and hydrophobic dyes-loaded 
polymeric MPs, synthesized by double emulsion method and characterized by confocal 
microscopy, have showed a localization of hydrophilic dye in the core of particles and the 
hydrophobic dyes in the shell structure of MPs (Lamprecht, 2000; Mao, 2007).  
The entrapment efficiency of Dex inside PHBV MPs was found to be influenced by the 
presence of ethanol in the organic phase during particle preparation. Based on the results, 
the incorporation efficiency of Dex was higher when adding ethanol to the process what 
can be explained by the dipole-dipole interaction with chloroform and its hydrogen bond 
with the water. Moreover, we hypothesize that the presence of the ethanol could promote 
the entrapment of Dex in the core, in similarity with what happens with the hydrophilic 
substances, by binding its apolar part to Dex while its hydrogen bond was connected to 
the water. Regarding the protein, BSA incorporation efficiency revealed to be independent 
of the organic phase composition. In this sense, comparing the results of both model 
bioactive molecules it is possible to observe that Dex has much higher incorporation 
efficiency than protein. As commonly seen in the double emulsion method, the 
incorporation of bioactive molecules is highly dependent on the chemical structure and 
molecular weight of the molecules, and hydrophobicity of the polymers (Park, 2005). 
Moreover, the PHBV hydrophobicity may not be compatible with the hydrophilicity of the 
protein, what can lead to a formation of an instable emulsion. Thus, the bioactive molecule 
entrapment efficiency was affected by organic phase composition and the incorporated 
active substance molecular weight. Lionzo et al. proposed a general single emulsion 
solvent evaporation technique for the incorporation of Dex within PHBV microspheres and 
the results appeared to be very similar with the results herein reported (Lionzo, 2007). 
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The in vitro release profile from a polymeric matrix is controlled by a variety of factors, 
namely the solubility of the drug within the surrounding media, the molecular weight of the 
bioactive substance, its mobility within the swollen polymeric network, as well as the 
dissolution rate of the polymer and polymer-drug interactions (Balmayor, 2009). 
Nevertheless, there are some other features that can have influence in the release kinetic, 
namely morphological characteristics of the particulate carriers, physicochemical 
characteristics of the polymer, and particle size and size distribution, which can be 
controlled, as previously described, by varying the conditions of the particles preparation 
procedure (Embleton, 1993; Saha, 1994; Igartua, 1997; Yang, 2001). 
Although PHAs have been described as high crystalline polymers (the reason for its slow 
degradation), excessive release rates from PHAs microspheres have been previously and 
consistently reported and assumed that the release phenomenon is more dependent on 
drug dissolution rather than matrix degradation or diffusion (Bidone, 2009). This was 
confirmed by the microscopic analysis of the MPs after the release studies that showed 
alterations in the surface of the systems but structurally intact and with spherical shape. 
Moreover, Independently of the conditions and of the incorporated molecules, the release 
profiles showed an initial burst phase, followed by a slower release, typical of a first order 
release kinetics. This behaviour is in accordance to what was described for other 
biodegradable polymers (Tuncel, 1995; Zignani, 1997; Hanes, 1998; Huang, 2001; 
Vandamme, 2002; Yoon, 2003). The in vitro release results indicated that more than 68% 
of Dex was released after 21 days from the particles produced in the absence of ethanol 
and 100% of Dex after 5 days from the particulate system produced in the presence of 
this solvent. Regarding the BSA release studies, no significant differences were observed 
when ethanol was added to the organic phase, and a release of protein around 78% was 
observed after 21 days of immersion. Accordingly with these observations, in the case of 
MPs produced with the absence of ethanol in the organic phase, the bioactive molecules 
release profile present a more sustained pattern when compared with the MPs where it 
was added ethanol. This finding, was expected since the addition of this alcohol to the 
organic phase creates larger pore size what can explain the higher drug release profile, 
since their presence facilitate the water penetration. 
Envisioning an administration improved by more precise spatial and temporal placement 
of the MPs within the organism, we propose the combination of the previous system with 
an injectable hydrogel. Injectable GG hydrogels have been extensively explored within our 
Research Group for a variety of TE and RM applications, by taking advantage of their 
thermal and ionic sensitivity thus allowing its gelation in situ (Oliveira, 2010; Coutinho, 
2010; Pereira, 2011).  
50 
 
In this sense, the incorporation of BSA- and Dex- loaded PHBV MPs within GG hydrogels 
envisioned as a long term release system with predefined control over release of proteins 
and/or glucocorticoids was developed. This biphasic system showed a uniform distribution 
of PHBV MPs across the GG matrix with a strong connection with the structure. However, 
the incorporation of the MPs into the GG hydrogels strongly influenced the profile and the 
released amount of both Dex and BSA. The previously observed differences with the 
processing conditions were reversed and the initial burst effect was eliminated. The 
microspheres entrapped into GG hydrogels showed a nearly zero-order release profile, 
which indicated that the combination of both systems causes a sustained release pattern. 
This phenomenon can be attributed to the high density of GG, which must limit the 
bioactive molecules diffusion. Additionally, the disintegration rate of the GG hydrogels was 
also verified after immersed in PBS for 3 weeks. It was observed that the hydrogel 
revealed some signs of degradation on the surface, which is in accordance with what was 
reported by Chang (2010). This evidence can be explained by hydrolytic reactions, being 
possibly exacerbate by the PHBV microspheres acidic degradation products.  
In summary, this work proved the capacity of PHBV microparticulate systems as a unique 
tool to deliver both hydrophilic and hydrophobic molecules, and the effect of the organic 
phase composition on their incorporation and respective release profile. Moreover, the 
embedding of this system with injectable hydrogel structures reinforced that the proposed 
system constitutes a suitable platform for being used as a sustained release system 
allowing, at the same time the modulation of the localization of particles obtained. The 
biphasic DDS herein described demonstrate the ability to deliver multiple bioactive 
molecules with distinct kinetics, in real-time, which is likely required to drive tissue 
development to regeneration. Furthermore, these systems also minimize the release of 
bioactive molecules, which constitutes an advantage considering that tissue regeneration 
normally occurs over long period of time frames (Biondi, 2008). 
 
5. Conclusion 
The main goal of this work was to develop a simple and versatile delivery platform, based 
on the combination of microparticulate systems and an injectable hydrogel, to carry 
hydrophilic and hydrophobic model bioactive substances relevant for TE purposes. In this 
sense, an injectable Gellan Gum hydrogel entrapping bioactive molecules-loaded PHBV 
microspheres has been prepared and characterized. Such platform showed the ability for 
being used as a long term release structure, which constitutes an advantage considering 
that tissue regeneration normally occurs over long period of time frames, offering at the 
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same time a high spatial control over polymeric particles distribution at the injection site. 
The proposed system provides a promising strategy for a variety of localized controlled 
drug delivery applications, namely in soft TE applications. 
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IV. Final Remarks and Future Perspectives 
The main goal of this work was to develop a simple and versatile delivery platform, based 
on the combination of microparticulate systems, carrying model bioactive substances 
relevant for Tissue Engineering and Regenerative Medicine purposes, and an injectable 
hydrogel. Such platform was expected to comprise features that would allow its 
application as a long term release DDS, offering a high spatial control over and enhanced 
resident time of polymeric particles upon injection. 
PHBV MPs were produced by means of a double emulsion solvent evaporation technique 
based on a previously reported methodology but with modifications. A mixture of 
chloroform and ethanol as organic phase was used with the expectation of tailoring the 
release profile of incorporated molecules by changing the physicochemical characteristics 
of PHBV microparticles. As expected, the addition of ethanol to the organic phase had 
great influence onto PHBV MPs surface topography, size distribution and surface and 
core porosity. Moreover, the presence of ethanol in the organic phase benefitted Dex 
incorporation but did not affect the entrapment efficiency of BSA. Thus, in addition to the 
processing conditions, the type and size of the molecules to be incorporated, in which Dex 
and BSA differ significantly, also influence the efficiency of loading. In his turn, the in vitro 
release profile studies confirmed an initial burst effect which was followed by a sustained 
pattern, typical of a first order release kinetics and in accordance to what has been shown 
for microparticulate polymeric DDS. 
An innovative approach that tackled the limitations of current microparticulate DDS when 
injected as a suspension into the site of injury, namely the reduced residence time and 
uncontrolled mechanical forces to which are subjected, was envisioned. The use of 
injectable GG hydrogel formulations, have been proposed for diverse tissue engineering 
applications and thus would not negatively affected host response, when considered as 
MPs carriers. A combined and well integrated system of PHBV MPs within a GG hydrogel 
was successfully achieved. This biphasic system was capable of long-term retention, in 
comparison to single PHBV microspheres, of the incorporated bioactive substances, 
remaining substantially intact.  
In this sense, a biphasic DDS, which allows the release of biochemical cues with different 
physicochemical features, as well as its localized deliver, was successfully developed and 
represents a versatile tool to prepare instructive cell microenvironments for TERM. 
60 
 
Further improvements can be foreseen in order to tune the release profile of the combined 
structures according to tissue and pathology/injury specific requirements. This will be 
attempted by tailoring the properties of the hydrogel, which has been extensively studied 
in our Research Group.  Moreover, studies to assess systems sensitivity to enzyme-driven 
degradation will be designed as it will certainly contribute for modulating the release 
kinetics of incorporated molecules.  
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V. Annex 
1. Morphological Analysis 
The SEM analysis of the Dex loaded-PHBV MPs show a similar spherical morphology as 
observed in the BSA-loaded PHBV MPs.  
 
 
 
 
 
 
 
  
 
Figure 1 - SEM micrographs of Dex loaded-PHBV MPs obtained under different experimental 
conditions: (A) using 100% chloroform; and (B) 90% chloroform: 10% ethanol. The sequential 
micrographs represent an overview of the obtained MPs showing the detail of their surface. 
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